April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma
Author Affiliations & Notes
  • T. G. Murray
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Y. Piña
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • S. Houston
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • E. Hernandez
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • M. Celdran
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • W. Feuer
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • T. Lampidis
    Cell Biology, University of Miami, Miami, Florida
  • Footnotes
    Commercial Relationships  T.G. Murray, None; Y. Piña, None; S. Houston, None; E. Hernandez, None; M. Celdran, None; W. Feuer, None; T. Lampidis, None.
  • Footnotes
    Support  Supported by NIH center grant R01 EY013629, R01 EY12651, and P30 EY014801; by the American Cancer Society, Sylvester Comprehensive Cancer Center; and by an unrestricted grant to UM
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2067. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. G. Murray, Y. Piña, S. Houston, E. Hernandez, M. Celdran, W. Feuer, T. Lampidis; Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2067.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The purpose of this study was to evaluate changes in tumor burden and hypoxic regions of LHBETATAG murine retinal tumors following treatment with the m-TOR inhibitor agent rapamycin.

Methods: : The study protocol was approved by the IACUC and follows ARVO guidelines. 17-week-old LHBETATAG retinal tumor eyes (n=50) were evaluated. Mice were divided into 6 groups and received periocular injections for three consecutive weeks of: (a) saline, (b) rapamycin (33.25mg/kg), (c) rapamycin (66.5mg/kg), (d) rapamycin (133mg/kg), (e) rapamycin (266mg/kg), and (f) rapamycin (267mg/kg) + 2-DG (500mg/kg). Treatment of rapamycin was given once a week and treatment of 2-DG was given bi-weekly. Eyes were enucleated at 20 weeks of age. To assess hypoxia, mice received 60mg/kg of pimonidazole via intraperitoneal injection. Eyes were enucleated and tumor sections were analyzed for hypoxia and tumor burden.

Results: : Eyes treated with rapamycin alone showed a significant decrease in tumor burden (p<0.001, two-tailed t-test) in comparison with the saline control group in all treatment groups. There is a dose response of tumor burden reduction in the eyes treated with rapamycin alone (p<0.001, two-way analysis of variance, ANOVA). Tumor burden and levels of hypoxia significantly decreased following treatment with the combination therapy of rapamycin and 2-DG. Comparison between eyes treated with rapamycin alone and eyes treated with a combination therapy of rapamycin and 2-DG showed a significant reduction of both hypoxia regions and tumor burden (p<0.001).

Conclusions: : This is the first report of LHBETATAG transgenic retinoblastoma tumors decreasing following the administration of the m-TOR inhibitor rapamycin administered alone or in combination with the glycolytic inhibitor 2-DG. This unique approach, utilizing cellular targeting of hypoxic pathways, may have benefits for children with retinoblastoma and warrants further translational investigation.

Keywords: retinoblastoma • tumors • clinical laboratory testing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×